Bullish Case: Washout complete: $40B erased on three discrete pipeline hits while 5–6% sales-growth guidance stands. Contango term structure (Oct IV 21.8% vs Nov 25.2%) says event premium cleared; Helium's PDF anchors $140 with recovery bumps at $145/$170. Remibrutinib Phase 3 wins, a Q4 del-zota FDA decision, ~4% yield, and Artisan-driven buyback/portfolio-pruning pressure give re-rating paths; oversold defensives historically mean-revert once binary risk passes.

Bearish Case: Three failures in six days—pelacarsen, CAR-T deaths, del-desiran—expose M&A discipline gaps; Artisan's board revolt risks strategic paralysis. Q3 (late Oct) likely books an Avidity impairment; Vontobel cut to CHF 125. Puts outtraded calls 50% at 109th-percentile volume. Macro compounds: Brent ~$99, PPI 5.4%, hawkish Fed, fat SPY downside skew. My August range broke—the priced put tail was the honest signal; both PDFs keep a $115 second-shock bump.

Potential Outcomes:

• 32% — Washout stabilizes: $145–152 (yield bid, activist/buyback support).
• 28% — De-rating: $128–136 (Q3 impairment late Oct, cuts, stagflation).
• 22% — Range $136–146; Nov 25.2% IV decays post-earnings.
• 10% — Second shock <$130 (new failure/CRL/340B ruling; $115 density bump).
• 8% — Surge $153–165 (del-zota approval, capital-return pivot).

Oracle: contango favors post-earnings premium capture—Dec 135P (24.7 IV) against Jan 115P hedge; delta-light through the late-Oct print; Jan 155C (23.7 IV) as cheap recovery optionality.

September 19, 2026